Omar L Francone

Summary

Publications

  1. pmc Disruption of the murine procollagen C-proteinase enhancer 2 gene causes accumulation of pro-apoA-I and increased HDL levels
    Omar L Francone
    Department of Cardiovascular and Metabolic Diseases, Global Research and Development, Pfizer, Inc, Groton, CT, USA
    J Lipid Res 52:1974-83. 2011
  2. ncbi request reprint Abnormal phospholipid composition impairs HDL biogenesis and maturation in mice lacking Abca1
    Omar L Francone
    Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Biochemistry 42:8569-78. 2003
  3. ncbi request reprint Increased cholesterol deposition, expression of scavenger receptors, and response to chemotactic factors in Abca1-deficient macrophages
    Omar L Francone
    Pfizer Global Research and Development, Department of Cardiovascular and Metabolic Diseases, Groton, CT 06340
    Arterioscler Thromb Vasc Biol 25:1198-205. 2005
  4. ncbi request reprint ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation
    Robert J Aiello
    Pfizer Global Research and Development, Department of Cardiovascular and Metabolic Diseases, Eastern Point Road, Groton, Conn 06340, USA
    Arterioscler Thromb Vasc Biol 23:972-80. 2003
  5. doi request reprint The PPARα agonists fenofibrate and CP-778875 cause increased β-oxidation, leading to oxidative injury in skeletal and cardiac muscle in the rat
    John C Pettersen
    Pfizer Worldwide Research and Development, Groton Laboratory, Pfizer, Inc, Groton, Connecticut 06340, USA
    Toxicol Pathol 40:435-47. 2012
  6. doi request reprint Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo
    Christopher D Kane
    Departments of Atherosclerosis Biology, Pfizer Global Research and Development, Pfizer Inc, Groton, Connecticut 06340, USA
    Mol Pharmacol 75:296-306. 2009
  7. doi request reprint The hydrophobic tunnel present in LOX-1 is essential for oxidized LDL recognition and binding
    Omar L Francone
    Department of Atherosclerosis Biology, Pfizer Global Research and Development, Groton, CT 06340, USA
    J Lipid Res 50:546-55. 2009
  8. pmc A critical role for peroxisomal proliferator-activated receptor-alpha nuclear receptors in the development of cardiomyocyte degeneration and necrosis
    Ingrid Pruimboom-Brees
    Pfizer Global Research and Development, Department of Cardiovascular and Metabolic Diseases, Eastern Point Rd, Groton, CT 06340, USA
    Am J Pathol 169:750-60. 2006
  9. ncbi request reprint ABCA1: regulation, function and relationship to atherosclerosis
    Omar L Francone
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Curr Opin Investig Drugs 3:415-9. 2002
  10. pmc Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1
    Jian Zhu
    Pfizer Global Research and Development, Department of Cardiovascular and Metabolic Diseases, Groton, CT 06340, USA
    J Lipid Res 50:1330-9. 2009

Collaborators

Detail Information

Publications12

  1. pmc Disruption of the murine procollagen C-proteinase enhancer 2 gene causes accumulation of pro-apoA-I and increased HDL levels
    Omar L Francone
    Department of Cardiovascular and Metabolic Diseases, Global Research and Development, Pfizer, Inc, Groton, CT, USA
    J Lipid Res 52:1974-83. 2011
    ..ABCA1-dependent cholesterol efflux is defective in PCPE2 KO mice, suggesting that the functionality of HDL is altered...
  2. ncbi request reprint Abnormal phospholipid composition impairs HDL biogenesis and maturation in mice lacking Abca1
    Omar L Francone
    Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Biochemistry 42:8569-78. 2003
    ..Taken together, these observations suggest that ABCA1 is necessary for the adequate lipidation of apoAI, which enables the interaction with LCAT and subsequent maturation...
  3. ncbi request reprint Increased cholesterol deposition, expression of scavenger receptors, and response to chemotactic factors in Abca1-deficient macrophages
    Omar L Francone
    Pfizer Global Research and Development, Department of Cardiovascular and Metabolic Diseases, Groton, CT 06340
    Arterioscler Thromb Vasc Biol 25:1198-205. 2005
    ..Therefore, we examined whether the absence of ABCA1 affects the morphology, properties, and functional activities of macrophages that could be related to the development of atherosclerosis...
  4. ncbi request reprint ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation
    Robert J Aiello
    Pfizer Global Research and Development, Department of Cardiovascular and Metabolic Diseases, Eastern Point Road, Groton, Conn 06340, USA
    Arterioscler Thromb Vasc Biol 23:972-80. 2003
    ..The phenotype of the ABCA1-deficient mouse parallels the phenotype observed in human Tangier disease, including substantial reductions in both apolipoprotein B and apolipoprotein AI with confounding affects on atherosclerosis...
  5. doi request reprint The PPARα agonists fenofibrate and CP-778875 cause increased β-oxidation, leading to oxidative injury in skeletal and cardiac muscle in the rat
    John C Pettersen
    Pfizer Worldwide Research and Development, Groton Laboratory, Pfizer, Inc, Groton, Connecticut 06340, USA
    Toxicol Pathol 40:435-47. 2012
    ..Taken together, these findings were consistent with PPARα agonism and support the link between increased cardiac and skeletal muscle β-oxidation and resultant muscle injury in the rat...
  6. doi request reprint Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo
    Christopher D Kane
    Departments of Atherosclerosis Biology, Pfizer Global Research and Development, Pfizer Inc, Groton, Connecticut 06340, USA
    Mol Pharmacol 75:296-306. 2009
    ..Whereas these compounds are efficacious in acute preclinical models, extended safety studies and further clinical testing will be required before the full therapeutic promise of a selective PPARalpha agonist is realized...
  7. doi request reprint The hydrophobic tunnel present in LOX-1 is essential for oxidized LDL recognition and binding
    Omar L Francone
    Department of Atherosclerosis Biology, Pfizer Global Research and Development, Groton, CT 06340, USA
    J Lipid Res 50:546-55. 2009
    ..These studies suggest that the central hydrophobic tunnel that extends through the entire LOX-1 molecule is a key functional domain of the receptor and is critical for the recognition of modified LDL...
  8. pmc A critical role for peroxisomal proliferator-activated receptor-alpha nuclear receptors in the development of cardiomyocyte degeneration and necrosis
    Ingrid Pruimboom-Brees
    Pfizer Global Research and Development, Department of Cardiovascular and Metabolic Diseases, Eastern Point Rd, Groton, CT 06340, USA
    Am J Pathol 169:750-60. 2006
    ..These findings suggest that activation of PPAR-alpha leads to increased cardiac fatty acid oxidation and subsequent accumulation of oxidative stress intermediates resulting in cardiomyocyte necrosis...
  9. ncbi request reprint ABCA1: regulation, function and relationship to atherosclerosis
    Omar L Francone
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Curr Opin Investig Drugs 3:415-9. 2002
    ....
  10. pmc Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1
    Jian Zhu
    Pfizer Global Research and Development, Department of Cardiovascular and Metabolic Diseases, Groton, CT 06340, USA
    J Lipid Res 50:1330-9. 2009
    ....
  11. doi request reprint Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus
    Steven G Terra
    Pfizer Global Research and Development, Groton, Connecticut, USA
    Am J Cardiol 102:434-9. 2008
    ..In conclusion, CP-778,875 2 mg/day significantly increased HDL cholesterol, significantly lowered fasting triglycerides, and increased apoA-I and HDL subfractions. The clinical relevance of the increase in homocysteine levels is unknown...
  12. ncbi request reprint Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages
    Robert J Aiello
    Pfizer Global Research and Development, Groton, Connecticut, USA
    Arterioscler Thromb Vasc Biol 22:630-7. 2002
    ..ABCA1 deficiency in macrophages, however, demonstrates the antiatherogenic properties of ABCA1 independent of plasma lipids and HDL levels...